Results from 31 January 2018 General Meeting

MELBOURNE, Australia, Jan. 31, 2018 --

Genetic Technologies Limited (ASX:GTG) (NASDAQ:GENE) (“Company”) advises that a General Meeting of shareholders that had been requisitioned pursuant to section 249D of the Corporations Act was held at 10.00 am today (Melbourne time).

At the commencement of the meeting, the appointed Chairman of the meeting, advised that resolution 1, removal of Dr Malcolm R. Brandon as a Director and resolution 2, removal of Mr Grahame Leonard, AM, as a Director had been withdrawn as a result of the resignations of these Directors.

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001(Cth), details of the proxies received in respect of each resolution put to shareholders are set out in Table 1 to this announcement. The four (4) resolutions that were put before the shareholders were passed on a show of hands.

FOR FURTHER INFORMATION PLEASE CONTACT

About Genetic Technologies Limited
Genetic Technologies is a molecular diagnostics company that offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead product, BREVAGenplus^®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class.  BREVAGenplus is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer.

The Company markets BREVAGenplus, through its U.S. subsidiary Phenogen Sciences Inc., to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons). For more information, please visit www.brevagenplus.com and www.phenogensciences.com.

Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com

Safe Harbor Statement
Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.

Table 1 - Proxy results for 31 January 2018 General Meeting

*Discretionary votes in favour of the Chair of the meeting – voted against the resolution

Note:      The Company currently has a total of 2,435,282,724 ordinary shares on issue and 3,596 registered shareholders.